NEW DELHI: Bharat Biotech’s Covaxin is said to have gotten approval from the Subject Expert Committee (SEC) on COVID-19 for emergency usage in children above the age of two in India.
According to reports, the SEC has filed recommendations to the Drugs Controller General of India (DCGI) for the vaccine’s approval for use on children.
Covaxin will become the only vaccination authorised for use on children and the only such vaccine for toddlers if it is approved. The three-dose DNA jab developed by Zydus Cadilla was approved for use on adults and children over the age of 12 in August.
In September, the Hyderabad-based business completed Phase 2 and Phase 3 studies of Covaxin on children under the age of 18.
The Serum Institute’s Novavax vaccine is a third potential vaccination for children, and the DCGI approved studies for youngsters aged seven to eleven years old last month.